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Abstract  
While the global incidence of cutaneous melanoma is increasing, survival rates for patients 
with metastatic disease remain less than 10%. Novel treatment strategies are therefore 
urgently required, particularly for patients bearing BRAF/NRAS wildtype tumours. Targeting 
autophagy is a novel means to promote cancer cell death in chemotherapy-resistant tumours 
and the aim of the present study was to test the hypothesis that cannabinoids promote 
autophagy-dependent apoptosis in melanoma. Treatment with 9-Tetrahydrocannabinol 
(THC) resulted in the activation of autophagy, loss of cell viability and activation of 
apoptosis, while co-treatment with chloroquine or knockdown of Atg7, but not Beclin-1 or 
Ambra1, prevented THC-induced autophagy and cell death in vitro. Administration of 
Sativex-like (a laboratory preparation comprising equal amounts of THC and cannabidiol 
(CBD)) to mice bearing BRAF wildtype melanoma xenografts substantially inhibited 
melanoma viability, proliferation and tumour growth paralleled by an increase in autophagy 
and apoptosis compared to standard single agent temozolomide. Collectively our findings 
suggest THC activates non-canonical autophagy-mediated apoptosis of melanoma cells, 
suggesting cytotoxic autophagy induction with Sativex warrants clinical evaluation for 
metastatic disease.  
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Introduction 
Cutaneous melanoma incidence continues to increase, and response rates of patients with 
metastatic melanoma to current therapy remain poor (Garbe et al., 2011).  Identification of 
driver mutations and development of targeted therapies to BRAF/MEK has revolutionised 
melanoma therapy, though clinical resistance is inevitable (Chen and Davies, 2014). The 
emergence of immunotherapies able to promote tumour T-cell responses are further changing 
melanoma management (Wolchok et al., 2010), however, not all patients respond (Prieto et 
al., 2012). It is therefore clear there is no consistently beneficial treatment for metastatic 
melanoma and alternative approaches should be explored.  
Autophagy (macroautophagy) is the principal lysosomal-mediated mechanism for the 
degradation of damaged or long-lived organelles and proteins. Under physiological 
conditions, autophagy maintains normal turnover of cellular components as well as 
responding to metabolic stress, while in pathological settings autophagy activation mediates 
defence against extracellular insults and pathogens (Choi et al., 2013). The current model for 
the role of autophagy in cancer is that in the early stages of tumour development, quality 
control by autophagy inhibits tumourigenesis, while in advanced cancer, autophagy provides 
energy to meet the increased demands and a means to resist cell death caused by cytotoxic 
therapy (White, 2012). Preclinical data suggest lysosomal inhibition can cause tumour 
regression, and the lysosome inhibitors chloroquine or hydroxychloroquine are now being 
evaluated in clinical trials either alone or in combination with chemotherapy (Yang et al., 
2011). However, recent studies suggest chloroquine/hydroxychloroquine treatment may 
promote tumour development (Michaud et al., 2011, Maycotte et al., 2012), questioning the 
benefit of autophagy inhibition. An alternative approach for autophagy modulation is via 
exacerbation; while initially this appears counterintuitive to treat advanced cancer, recent 
evidence suggests that in particular circumstances a consequence of autophagy activation is 
cell death (Ding et al., 2007, Scarlatti et al., 2008, Tomic et al., 2011, Basit et al., 2013). 
Therapeutic exploitation of cytotoxic autophagy to drive cancer cell death is therefore an 
emerging concept for the development of novel cancer treatments. 
Cannabinoids are a diverse class of compounds derived from Cannabis sativa, with Δ9-
tetrahydrocannabinol (THC) the most relevant owing to its high potency and abundance 
(Pertwee, 2008). THC exerts its biological effects by mimicking endocannabinoids, which 
bind to and activate two G protein-coupled cannabinoid receptors, CB1 and CB2 (Howlett et 
al., 2002). CB1/CB2 receptors are expressed in many cancer cell types (Velasco et al., 2012), 
and cannabinoids are currently being investigated as anti-cancer agents, including 
glioblastoma for which THC has shown considerable promise (Velasco et al., 2012). 
Preclinical data demonstrate THC exerts its anti-tumoural action via induction of 
endoplasmic reticulum (ER) stress, up-regulation of the transcriptional coactivator p8 and the 
pseudo-kinase tribbles homologue 3 (TRIB3), the stimulation of autophagy and execution of 
apoptosis (Carracedo et al., 2006, Salazar et al., 2009a, Salazar et al., 2009b). Blockade of 
autophagy prevents THC-induced apoptosis and cell death, indicating autophagy is upstream 
of apoptosis and demonstrating the potential of p8/TRIB3-mediated autophagy as a cytotoxic 
pathway.  
Alongside genetic changes, adaption to ER stress and the aberrant control of autophagy have 
emerged as key drivers of malignancy and therapy resistance in advanced melanoma 
(Armstrong et al., 2011, Corazzari et al., 2013). The cannabinoid receptors have previously 
been identified as potential therapeutic targets (Blazquez et al., 2006, Carracedo et al., 2006), 
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hence targeting ER stress responses combined with cytotoxic autophagy using cannabinoids 
may represent a valuable therapeutic approach for metastatic melanoma. The aim of this 
study was to determine whether THC activates cytotoxic autophagy in melanoma cells in 
vitro and in vivo. Our data suggest a non-canonical mechanism of autophagy-mediated 
apoptosis, highlighting the potential to harness autophagy for therapeutic benefit in advanced 
melanoma. 
 
 
Results  
THC activates autophagy and apoptosis in melanoma cells 
Characteristic features of early and late stages of autophagy were assessed using LC3 
lipidation (LC3-II) and analysis of autophagic flux using chloroquine and visualization of 
tandem mRFP-GFP–tagged LC3 (Kimura et al., 2007) respectively. LC3-II induction was 
observed in three human melanoma cell lines in response to THC, and LC3-II accumulated 
further in the presence of chloroquine in both BRAF wildtype (CHL-1) and mutated (A375, 
SK-MEL-28) melanoma cells. Additionally, increased numbers of LC3-positive 
autophagosomes (yellow puncta) and autolysosomes (red puncta), and total red fluorescence 
(CHL-1: t43=4.17, P < 0.001; A375: t42=3.289, P = 0.002) were observed in A375 and CHL-1 
cells in response to THC treatment, indicating activation of autophagic flux (Fig. 1). 
 
THC reduced melanoma cell viability in a dose-dependent manner while having little effect 
on primary melanocytes at doses up to 6 M THC (Fig. 2a). Co-treatment of melanoma cells 
with sub-maximal concentrations of THC and the pan-caspase inhibitor ZVAD-fmk 
significantly increased cell viability compared to treatment with THC alone (CHL-1: 
t22=3.962, P=0.0007; A375: t16=3.74, P=0.0018; Fig. 2b) suggesting cell death is caspase-
dependent. In addition, the cytochrome c-labelled structures present in vehicle-treated cells 
were substantially reduced in THC-treated cells (Fig. 2c), indicating apoptosis activation.   
 
THC-induced apoptosis is dependent on autophagy 
In glioma THC activates apoptosis via a mechanism involving TRIB3 and Beclin-1-
dependent autophagy (Carracedo et al., 2006, Salazar et al., 2009b). SiRNA-mediated 
knockdown of TRIB3 significantly prevented loss of cell viability in response to THC in 
A375 cells (one-way ANOVA; F5,48=5.053, P=0.001; THC compared to vehicle treatment in 
siCtrl cells; Tukey’s P < 0.05; Supplementary Fig. 1) demonstrating TRIB3 mediates THC-
induced cell death. Furthermore, siRNA-mediated knockdown of Atg7 prevented THC-
induced accumulation of LC3-II in the presence of chloroquine (one-way ANOVA; 
F11,24=6.878, P < 0.001; CQ compared to CQ+THC treated siCtrl cells contrast P < 0.05; Fig. 
3A,B). THC-induced caspase 3 cleavage was also inhibited by Atg7 knockdown in A375 
(Fig. 3a) as well as in CHL-1 and SK-MEL-28 cells (CHL-1: one-way ANOVA; F5,12=6.57, 
P=0.004; THC compared to vehicle-treated siCtrl cells; Tukey’s P < 0.05; SK-MEl-28: one-
way ANOVA; F3,8 =4.646, P=0.037; THC compared to vehicle-treated siCtrl cells; Tukey’s P 
< 0.05; Supplementary Fig. 2). Additionally, THC treatment resulted in a significant loss of 
melanoma cell viability only in the absence of chloroquine or Atg7 siRNA (Fig. 3, 
Supplementary Fig. 2; post hoc tests, Games-Howell or Tukey’s P < 0.01). In A375 and SK-
MEL-28 cells, knockdown of Atg7 alone had no effect on cell viability; however, in CHL-1 
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cells down-regulation of Atg7 resulted in a significant loss of cell viability (Tukey’s P < 
0.001; Supplementary Fig. 2a) suggesting basal autophagy is required to maintain viability in 
these cells. Collectively these data demonstrate THC-induced apoptosis of melanoma cells 
requires TRIB3 and is mediated by Atg7-dependent autophagy. 
 
Beclin-1 promotes autophagy induction and autophagosome formation (Russell et al., 2013); 
however, Beclin-1-independent autophagy has been reported (Scarlatti et al., 2008, Grishchuk 
et al., 2011). Unlike in glioma cells, Beclin-1 knockdown did not prevent THC-induced LC3-
II accumulation or caspase 3 cleavage (t4=4.494, P=0.011; Supplementary Fig. 3a) in A375 
cells (Fig. 4a), and THC treatment resulted in a significant loss of cell viability under both 
control and Beclin-1 knockdown conditions (Welch ANOVA; F5,19.63 = 94.53, P<0.001; THC 
treatments compared to vehicle-treated shRNA cells; Games-Howell P < 0.001; Fig. 4a-iii). 
These results suggest autophagy and subsequent apoptosis occur independently of Beclin-1. 
Furthermore, knockdown of the Beclin-1 interacting protein Ambra1 failed to prevent THC-
induced LC3-II induction and caspase 3 cleavage (t4=6.097, P=0.004; Supplementary Fig. 3b; 
Fig. 4b). The effect of Ambra1 knockdown alone on A375 viability was variable, however, 
THC treatment resulted in a significant loss of cell viability under both control (t16=9.44, 
P<0.001) and Ambra1 knockdown conditions (t16 =10.61, P<0.001) (Fig. 4b-iii). 
Collectively, these data suggest THC activates non-canonical autophagy-mediated apoptosis 
of melanoma cells which is dependent on Atg7 but not Beclin-1 or Ambra1. 
 
Cannabinoid treatment stimulates autophagy and apoptosis, and the abrogation of 
melanoma growth in vivo 
A 1:1 mixture of sub-maximal doses of THC-botanical drug substance (BDS) and the non-
psychoactive cannabinoid CBD-BDS, a laboratory mimic of the clinical cannabinoid Sativex 
(Sat-L) (an oromucosal spray of standardized cannabis extract comprising equal amounts of 
THC and CBD (GW Pharmaceuticals)), reduced glioma growth in vivo to the same extent as 
an identical dose of THC (Torres et al., 2011). Treatment of melanoma cells with THC+CBD 
resulted in a substantial loss of melanoma cell viability at a concentration of 1 M THC + 1 
M CBD in CHL-1, A375 and SK-MEL-28 cells compared to equivalent concentrations of 
THC, while temozolomide had little effect (Fig. 5). Temozolomide is an alkylating agent 
currently indicated as standard single-agent chemotherapy for metastatic melanoma. The in 
vivo relevance of these findings was evaluated in the context of BRAF wildtype melanoma 
tumours, for which there is a particular demand for novel therapeutic approach in the absence 
of targeted therapies in this tumour group. CHL-1 xenograft tumours were treated for 20 days 
with temozolomide, THC or Sativex-like. Both THC and Sativex-like significantly inhibited 
the growth of xenografts (one-way ANOVA; F3,16=9.347, P=0.001; THC or Sat-L compared 
with vehicle, Sat-L compared to Temozolomide: P<0.05, Fig. 6a). Tumours removed from 
animals at sacrifice were processed for immunohistochemical analysis of proliferative 
activity (Ki67), apoptosis (TUNEL) and autophagy (LC3). Ki67 fluorescence differed 
significantly between drug treatments (Welch ANOVA; F3,16.28 =61.363, P < 0.001; Fig. 6b), 
and was significantly reduced in tumours from animals treated with temozolomide, THC or 
Sativex-like compared to control animals (Games-Howell; P≤0.001), as well as in tumours 
from animals treated with THC or Sativex-like compared to those treated with temozolomide 
(Games-Howell; P<0.001). TUNEL fluorescence also differed significantly between 
treatments (one-way ANOVA; F3,32=13.31, P<0.001), and was higher than control in tumours 
from animals treated with THC or Sativex-like (Tukey’s’ P≤0.001), and higher in tumours 
from animals treated with Sativex-like compared to those treated with temozolomide 
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(Tukey’s; P<0.05) (Fig. 6c). Correspondingly, LC3 fluorescence differed between treatments 
(one-way ANOVA; F3,32=3.539, P<0.05), with significantly increased LC3 staining in 
tumours from animals treated with Sativex-like compared to tumours from animals treated 
with vehicle or temozolomide (Tukey’s: P≤0.05, Fig. 6d). Staining for Ki67, TUNEL and 
LC3 were not significantly different in tumours from animals treated with THC compared to 
Sativex-like. Collectively these data suggest THC and Sativex-like are more effective than 
temozolomide in terms of apoptosis induction and anti-tumour response, further validating 
the therapeutic relevance of cannabinoid treatment for melanoma.  
 
 
 
Discussion 
It is apparent that autophagy modulation may offer considerable benefit in cancer treatment; 
however, potential drawbacks to autophagy inhibition have recently been identified (Michaud 
et al., 2011, Maycotte et al., 2012, Takahashi et al., 2012, Rosenfeldt et al., 2013). Emerging 
evidence indicates activation of autophagy can, in some circumstances, promote cell death; 
stimulation of cytotoxic autophagy therefore represents a novel approach to autophagy 
modulation (Ding et al., 2007, Scarlatti et al., 2008, Salazar et al., 2009b, Grishchuk et al., 
2011, Tomic et al., 2011, Basit et al., 2013). Here, we show that the cannabinoid THC exerts 
its anti-tumour effect on melanoma cells via activation of non-canonical autophagy and 
subsequent apoptosis, suggesting cannabinoids may be of clinical benefit for metastatic 
melanoma.  
The molecular mechanisms connecting autophagy to cell death remain poorly understood 
(Shen and Codogno, 2011), however, reports describing autophagy-dependent apoptosis 
(Ding et al., 2007, Salazar et al., 2009b, Grishchuk et al., 2011, Tomic et al., 2011) suggest 
multiple interactions between autophagic and apoptotic machinery. THC exerts its effect via 
the de novo synthesis of the sphingolipid ceramide, leading to the activation of ER stress, 
TRIB3-dependent inhibition of Akt/mTORC1 signalling and autophagy-mediated apoptosis 
(Carracedo et al., 2006, Salazar et al., 2009b). TRIB3 has been identified as a key switch 
between cell survival and apoptosis during stress responses (Shimizu et al., 2012), and the 
participation of TRIB3 in the melanoma response to THC may direct cellular fate towards 
apoptosis in the context of ER stress-induced autophagy (Salazar et al., 2013).  
Autophagy inhibition using both molecular and pharmacological approaches prevented THC-
induced autophagy and apoptosis of melanoma cells. However, THC-induced autophagy was 
not prevented by knockdown of Beclin-1, suggesting in contrast to glioma, non-canonical 
autophagy mediates apoptosis in response to THC in melanoma. Beclin-1-independent 
autophagy may promote caspase-independent cell death (Scarlatti et al., 2008, Basit et al., 
2013) as well as apoptosis (Grishchuk et al., 2011, Tomic et al., 2011) suggesting autophagy 
mechanisms not involving Beclin-1 exist which interact with cell death machinery. 
Interestingly, in contrast to previous studies (Salazar et al., 2009b), THC-induced autophagy 
was also independent of Ambra1 in melanoma cells. Ambra1 is a Beclin-1 interacting protein 
which promotes autophagy by stabilising Beclin-1 complexes (Fimia et al., 2007); while 
supporting the concept of Beclin-1-independent autophagy activation in response to THC, 
these data highlight the complex regulation of autophagy which likely occurs in a cell type- 
and context-specific manner.   
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Tumour-selective killing can be achieved by targeting pathways which are differentially 
regulated in cancer cells compared to normal cells. In this respect, we have shown that 
normal human melanocytes are resistant to THC at concentrations which cause cell death in 
melanoma cells. This is consistent with studies showing cancerous cells are more sensitive to 
THC and other cannabinoid receptor ligands than their non-transformed counterparts, despite 
the presence of functional CB receptors (Velasco et al., 2012). Together with previous studies 
demonstrating an effect of synthetic ligands of cannabinoid receptors in melanoma (Blazquez 
et al., 2006), these data support clinical evaluation of cannabinoids in advanced stage disease. 
Furthermore, THC activates autophagy and apoptosis in both BRAF wildtype and mutated 
melanoma cell lines, suggesting that despite autophagy deregulation (Corazzari et al., 2013,   
Armstrong et al., 2011), THC is likely effective in melanoma tumours regardless of BRAF 
mutation status. Furthermore, our findings show that THC is able to reduce melanoma cell 
viability and tumour xenograft growth alone, but when lower doses of THC are combined 
with CBD the anti-tumour effect was enhanced in vitro and at least equally effective as the 
higher dose of single-agent THC in vivo. Moreover, CBD induces apoptosis via the 
production of reactive oxygen species and caspase activation in cancer cells (Massi et al., 
2006, Shrivastava et al., 2011), indicating THC and CBD engage different molecular 
machinery which cooperate to promote tumour cell death (Shrivastava et al., 2011, Torres et 
al., 2011).  
In summary, these data highlight the potential for cannabinoid-induced cytotoxic autophagy 
as an effective strategy to drive melanoma cell death, supporting the clinical evaluation of 
Sativex for the treatment of metastatic disease. 
 
 
Materials and Methods 
Cell culture, viability assays, and drug treatment 
Melanoma cell lines CHL-1, A375, and SK-MEL-28 were obtained from the American Type 
Culture Collection in 2006 and cultured as described previously (Armstrong et al., 2007). 
Cell lines were verified by melan A staining (Flockhart et al., 2009) with B-RAF/NRAS 
mutational status confirmed using Custom TaqMan SNP genotyping assays (Hiscutt et al., 
2010) (Applera Europe BV) (last tested February 2014). Prior to drug treatment, culture 
medium was changed to 0.5% FBS medium. Temozolomide (OSI Pharmaceuticals), and 
ZVAD-fmk (benzyloxycarbonyl-V-A-D(OMe)-fluoromethylketone) (Tocris Bioscience, 
Bristol, UK) were added in DMSO, and chloroquine (Sigma) was added in water. For in vitro 
experiments, pure 9-tetrahydrocannabinol (THC) (THC Pharm, Frankfurt, Germany), and 
CBD (synthesised by Professor Mechoulam and kindly provided by Dr Fernandez Ruiz) were 
prepared in DMSO. Control incubations contained the same amount of DMSO (0.1-0.2% 
v/v). For treatment with THC+CBD, pure THC and pure CBD were mixed 1:1 (w/w). 
Analysis of cell viability was performed using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT; Sigma). For in vivo experiments, THC-botanical drug 
substance (THC-BDS; THC content 67.6% w/w; cannabidiol (CBD) content 0.3% w/w; other 
individual plant cannabinoids <1.5% w/w), and CBD-botanical drug substance (CBD-BDS; 
CBD content 65.4% w/w; THC content 2.5% w/w; other individual plant cannabinoids 
<1.7% w/w) were provided by GW Pharmaceuticals. THC-BDS, and CBD-BDS were 
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provided as a resin, dissolved in ethanol (100 mg/mL), dried and prepared in DMSO. A 1:1 
(w/w) preparation of THC-BDS and CBD-BDS was used to mimic Sativex (Sativex-like; Sat-
L). For oral administration THC or Sat-L was solved in 100 µl of sesame oil. 
 
Western blotting and RT PCR analysis 
Preparation of whole-cell lysates and Western blotting for LC3B, cleaved caspase 3 (Cell 
Signalling Technology), Atg7 (Santa Cruz Biotechnology), Beclin-1 (BD Biosciences), and 
Ambra1 (Novus Biologicals) all diluted 1:4000, and β-actin (Sigma) diluted 1:30000, were 
performed as described previously (Armstrong et al., 2007). Total RNA was isolated from 
cells using the RNeasy Mini Kit with DNase digestion (Qiagen) according to the 
manufacturer’s protocol. Reverse transcription (RT)-PCR was performed using the Access 
RT-PCR system (Promega) using primers for TRIB3 (Carracedo et al., 2006) or ß-actin 
(Armstrong et al., 2005). PCR products were analysed by electrophoresis on ethidium 
bromide-stained 2% agarose gels and DNA visualised by exposure to UV light.  
 
siRNA transfections 
siRNA for Atg7 (HSS116182), TRIB3 (sc-44426, Santa Cruz Biotechnology) or a non-
targeting siRNA (Negative control Low GC Stealth RNAi) (Stealth RNAi, Life 
Technologies) were transfected into cells in OPTIMEM containing siRNA (2-4 nM) using 
Lipofectamine RNAiMAX (Life Technologies) according to the manufacturer’s specification 
for reverse transfection. After 24 hours medium was replaced with DMEM containing 0.5% 
FBS and cells treated with drugs as appropriate.  
 
Retroviral or lentiviral infection  
Retroviral expression of mRFP-GFP-LC3 (provided by T. Yoshimori, Osaka University, 
Japan) (Kabeya et al., 2000, Kimura et al., 2007) was performed as described previously 
(Armstrong et al., 2011). Lentiviral expression of shAmbra1 or a non-targeting sequence 
shCtrl (MISSION shRNA, Sigma) was performed by cotransfection of 7.5 g lentivirus 
vector (pLKO.1-puro) with 2.5 g of an expression plasmid for the vesicular stomatitis virus 
G protein into 293 cells using the calcium precipitation method. After 48 hours, melanoma 
cells were incubated with virus-containing supernatant supplemented with polybrene (4 
μg/mL) for 6–8 hours, and selected for puromycin resistance. Lentiviral expression of 
shBeclin-1 (V3LHS_349509, Dharmacon)  or a non-targeting sequence shCtrl (RHS4346, 
Dharmacon) was performed by cotransfection of 20 g lentivirus vector with 5 g of an 
expression plasmid for the viral envelope (pMD2.G) and 15 g packaging plasmid  
(pCMVdelta8.91) into HEK293T cells using the calcium precipitation method. After 72 
hours, melanoma cells were spin-transduced (1.5 hours, 1200 RPM, Harrier 15/80) with 
virus-containing supernatant supplemented with polybrene (4 μg/mL) and selected for 
puromycin resistance.  
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Confocal microscopy 
Cells were grown on glass coverslips before fixation in 4% paraformaldehyde. For 
immunolabelling, cells were incubated with 0.2% Triton X-100 prior to incubation with anti-
cytochrome c (BD Biosciences) at room temperature for 1 hour (McGill et al., 2005). 
Secondary labelling was performed with Oregon Green 488 conjugated to anti-rabbit IgG 
(Life Technologies). Nuclei were counterstained with TO-PRO-3 iodide (Invitrogen). Cells 
were imaged under a Leica TCS SP II laser-scanning confocal microscope with LCS Lite 
2.61 software (Leica Microsystems), using a 63 x oil objective. 
 
Xenograft mouse model and immunohistochemical analysis 
Athymic nude (nu/nu) 5-week-old male mice (Harlan Iberica Laboratory, Spain) were 
inoculated by subcutaneous injection of 7.5 × 106 CHL-1 cells in 100 μL PBS containing 
0.1% glucose. On establishment of tumours 250 mm3 in volume, mice were randomized into 
four treatment groups (5–8 mice per group) and treated by daily administration for 20 days 
with Temozolomide (TMZ; 5 mg/kg, local - peritumoural injection), THC (15/mg/kg, oral 
gavage), or Sativex (7.5 mg/kg THC-BDS + 7.5 mg/kg cannabidiol (CBD)-BDS, oral 
gavage). The control group was treated with 100 μL of vehicle (sesame oil). Caliper 
measurements of tumour length (l) and width (w) were taken each day, and tumour volume 
calculated as (4π/3) x (w/2)2 x (l/2). Mice were humanely killed on the final day of treatment, 
and tumours extracted and snap frozen in liquid nitrogen before storage at −80°C. Frozen 
sections (6 μm) prepared on (3-Aminopropyl)triethoxysilane (Sigma)–coated glass slides 
were fixed in 4% paraformaldehyde before staining by terminal deoxyribonucleotide 
transferase–mediated dUTP-X nick-end labeling (TUNEL) or with a Ki67 antibody (ab-
15580, Abcam) as previously described (Hill et al., 2009). For LC3 immunolabelling, frozen 
sections were fixed in acetone and incubated with anti-LC3B (ab48394, Abcam) for 1 hour at 
room temperature. Secondary labelling was performed with Oregon Green 488 conjugated to 
anti-rabbit IgG (Life Technologies). Cells were imaged under a Leica TCS SP II laser-
scanning confocal microscope with LCS Lite 2.61 software (Leica Microsystems), using a 63 
x oil objective. 
 
Statistical analysis   
Images of LC3, Ki67 and TUNEL staining were analysed using Velocity (v4.3.1) 
(Improvision Ltd). Total fluorescence was obtained by multiplying pixel number to the mean 
pixel intensity, after appropriate thresholding. TOPRO-3 fluorescence was determined by the 
number of pixels with fluorescence above the threshold, which was proportional to nuclei 
number. For each tumour (3 animals per group, 3 randomly selected images each), values 
were reported as normalised total fluorescence (total fluorescence (LC3/Ki67/TUNEL) / total 
nuclear fluorescence) and expressed as fold change relative to the mean value obtained from 
control animals, from two independent staining analyses. mRFP fluorescence was analysed 
using ImageJ; data are total pixel intensities/cell minus the mean background fluorescence of 
nuclei. Homogeneity of variances were checked using Levene’s test and if variances were 
equal (normalised data or after log transformation) data were analyzed by drug treatment with 
the use of Student’s T test or using one-way ANOVA with planned contrasts (LC3 
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expression) or with Tukey's post hoc test for multiple pair-wise comparisons. Where 
variances were not equal, Welch ANOVA test was used with Games-Howell post hoc tests 
for pair-wise comparisons (SPSS Statistics 20 (SPSS Inc.)). 
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Figure Legends 
 
Figure 1. THC induces autophagy in melanoma cells.  
a,b,c, A375, SK-MEL-28 and CHL-1 cells were treated with vehicle or THC (4.5 or 5 M) 
for 24 hours, in the presence or absence of chloroquine (CQ; 10 M) for the final 2 hours, 
and LC3 and -actin expression determined by Western blotting. LC3-II expression was 
quantified and band intensity normalized to -actin. Data are expressed as fold change 
relative to the mean LC3-II/-actin value for a representative experiment and are shown 
above the western blot (representative data from n = 3 independent experiments). D, E, 
mRFP-GFP-LC3 expressing A375 (d) or CHL-1 (e) cells were treated with vehicle or THC 
(4.5 M) for 18 hours. Data are representative fluorescent micrographs (bar, 20 m) of three 
independent experiments. f, total red fluorescence values were generated from ≥ 20 cells per 
treatment condition, from two independent experiments. Pixel intensities were divided by a 
factor of 106 , and data are shown as mean ± SD (** P < 0.01, *** P < 0.001 versus control 
for each cell line).   
 
Figure 2. THC induces apoptosis of melanoma cells. 
a, primary melanocytes, A375, and CHL-1 cells were treated with vehicle or THC (3-10 M) 
for 24 hours. b, A375 (i) or CHL-1 (ii) cells were treated with vehicle or THC (5 M) in the 
presence or absence of ZVAD (20 M) for 24 hours. Cell viability was determined by MTT 
assay. Data generated in triplicate were expressed relative to the mean of vehicle-treated cells 
in each experiment, for three independent experiments, and shown as mean ± SD (T-test; ** 
P < 0.01, *** P < 0.001 versus THC+ZVAD). C, A375 cells were treated with THC (5 M) 
for 24 hour. Data are representative fluorescent micrographs of cytochrome c 
immunostaining (bar, 20 m) of three independent experiments. 
 
Figure 3. THC-induced apoptosis requires autophagy 
a,b,c, A375 cells were transfected with siRNAs for Atg7 (siAtg7) or with a nonsilencing 
control siRNA (siCtrl) before treatment with vehicle or THC (4.5, 5 M) for 24 hours, in the 
presence or absence of chloroquine (CQ; 10 M) for the final 2 hours (a,b) or for 24 hours 
(c). a,b, Atg7, LC3, cleaved caspase 3 and -actin expression were determined by Western 
blotting. LC3-II expression was quantified and band intensity normalized to -actin. Data are 
expressed as fold change relative to the mean LC3-II/-actin value for each experiment, for 
three separate experiments (mean ± SD, n = 3). c, Cell viability was determined by MTT 
assay. Data generated in triplicate were expressed relative to the mean of vehicle-treated 
siCtrl cells in each experiment, for three independent experiments, and shown as mean ± SD 
(* P < 0.05, ** P < 0.01, *** P < 0.001 versus vehicle treated siCtrl cells). 
 
Figure 4. THC-induced autophagy and cell death is not dependent on Beclin-1 or Ambra1 
a, A375 cells stably expressing shRNA for Beclin-1 (shBeclin1) or a nonsilencing control 
shRNA (shCtrl) were treated with vehicle or THC (4.5, 5 M) for 48 hours, in the presence 
or absence presence of chloroquine (CQ; 10 M) for the final 2 hours (i). Beclin-1, LC3, 
cleaved caspase 3 and -actin expression were determined by Western blotting (i). Cell 
viability (ii) was determined by MTT assay. Data generated in triplicate were expressed 
relative to the mean of vehicle-treated shCtrl cells in each experiment, for three independent 
experiments, and shown as mean ± SD (*** P < 0.001 versus vehicle treated shCtrl cells). b, 
A375 cells stably expressing shRNA for Ambra1 (shAmbra1) or a nonsilencing control 
shRNA (shCtrl) were treated with vehicle or THC (5 M) for 24 hours, in the presence or 
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absence of chloroquine (CQ; 10 M) for the final 2 hours (i). Ambra1, LC3, cleaved caspase 
3 and -actin expression were determined by Western blotting (i). Cell viability (ii) was 
determined by MTT assay. Data generated in triplicate were normalised to the mean of 
vehicle-treated cells for each shRNA in each experiment, for three independent experiments, 
and shown as mean ± SD (*** P < 0.001 versus vehicle treated cells for each shRNA). 
 
Figure 5. Cannabinoids inhibit melanoma cell viability in vitro 
a,b,c, CHL-1 (a), A375 (b) or SK-MEL-28 (c) cells were treated with Temozolomide (Temo; 
10-50 M), THC (1-5 M) or THC+CBD (0.5 M THC + 0.5 M CBD to 2.5 M THC + 
2.5 M CBD) for 48 hours. Cell viability was determined by MTT assay. Data generated in 
triplicate were expressed relative to the mean of vehicle-treated cells for each drug treatment 
in each experiment, for three independent experiments, shown are mean ± SD for a 
representative experiment. 
 
Figure 6. THC and Sativex-like cannabinoids promote autophagy and anti-tumour responses 
in melanoma xenografts 
Athymic nude mice were injected subcutaneously in the right flank with CHL-1 melanoma 
cells. When tumours reached a 250 mm3 size, mice were treated daily for 20 days with 
vehicle, Temozolomide (TMZ; 5 mg/kg; local administration), THC (15/mg/kg; oral 
administration), or Sativex-like (Sat-L; 7.5 mg/kg THC-BDS + 7.5 mg/kg CBD-BDS; oral 
administration). a, Tumour volumes were measured daily. Each point is the mean from ≥ 5 
tumours ± SD and is expressed relative to the tumour volume on day 1 of treatment. b,c,d 
Immunohistochemical analysis of CHL-1 xenograft tumours treated with Temozolomide, 
THC or Sat-L. Panels B, C and D are micrographs of tumour sections stained for Ki67 (b), 
TUNEL (c) or LC3 (d). In each, green is staining for Ki67, TUNEL or LC3, and red is the 
TO-PRO-3 counterstain. The bar graphs below each set of micrographs summarise the data 
analysis from tumour sections (bar, 20 m). Total fluorescence values (total fluorescence 
(LC3/Ki67/TUNEL) / total nuclear fluorescence) were generated in triplicate for 3 tumours in 
each treatment group. Data are expressed as fold change relative to the mean value obtained 
from control animals, from two independent staining analyses, and shown as mean ± SD (** 
P < 0.01, *** P < 0.001 versus control animals). 
 









